Latest news with #TelixPharmaceuticals
Yahoo
04-06-2025
- Business
- Yahoo
Telix Pharmaceuticals (ASX:TLX) Gains Portugal Approval for Illuccix in Prostate Cancer Detection
Telix Pharmaceuticals recently gained marketing authorization for its prostate cancer imaging agent, Illuccix®, in Portugal. This development enhances diagnostic options in a country where prostate cancer is prevalently diagnosed. Last week, the company's share price rose by 3%, a move that aligns with its recent regulatory success. Although the broader market remained steady over the same period, Telix's approval could provide additional support to its stock performance. The growth in Telix's share price complements the longer-term market trend, with broader market earnings expected to grow annually, positioning the company favorably. We've discovered 1 risk for Telix Pharmaceuticals that you should be aware of before investing here. We've found 20 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Over the past five years, Telix Pharmaceuticals has delivered a tremendous total shareholder return of 1863.90%. In the past year, Telix's performance surpassed the Australian Biotechs industry, which saw a 10.2% decline, highlighting the company's robust and resilient market position. The recent marketing authorization for Illuccix® in Portugal is expected to bolster revenue streams, complementing the company's efforts to expand its presence across international markets. These developments align with revenue forecasts expecting annual growth of 19.5%, outpacing the broader Australian market's expected growth of 5.6% annually. Telix's earnings forecasts also suggest promising growth, projected to rise significantly at 33.2% per year, compared to the market's 11.7%. This is supported by the company's strategic approvals and existing product portfolio, contributing to upward earnings revisions. The current share price movement, slightly below the consensus analysts' price target of A$32.05, suggests that there may be potential for further share price appreciation as the company continues to execute its growth strategy. The recent developments reinforce investor confidence in Telix's ability to sustain its growth trajectory in a competitive industry landscape. Gain insights into Telix Pharmaceuticals' past trends and performance with our report on the company's historical track record. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:TLX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
News.com.au
22-05-2025
- Business
- News.com.au
Health Check: ‘Forgotten' drug maker AFT Pharma aims high with revenue
AFT Pharmaceuticals boosts revenue, but profits still lag Telix Pharmaceuticals chair and CEO reflect on a prosperous 2024 – and promise more riches to come Dimerix's pivotal trail passes another safety check The bourse's 'forgotten' drug maker, Kiwi-based AFT Pharmaceuticals (ASX:AFP) is confident of reaching its 'aspirational' target of $NZ300 million ($270 million) of revenue within the next two years. This comes after the company posted a record turnover of $NZ208 million for the year to March, up 6%. 'AFT is well positioned to achieve this target,' said CEO and co-founder Dr Hartley Atkinson. 'While the global trading environment is looking more difficult, we are confident that we can continue to overcome these challenges by focusing on what we do best.' 'What we do best' is identifying unmet needs and then in-licensing or developing medicines to commercialisation. Often these are drugs for conditions overlooked by big pharma. AFT reported operating profit came in at NZ$17.6 million, as per guidance but down 27% year on year. Net profit declined 23% to NZ$12 million. The company said its performance was crimped by some significant 'one off' events flagged in the first half. These included destocking by customers and the prolonged doctors' strike in South Korea. Bulging medicine cabinet AFT's products cover everything from pain, eyecare, dermatology, gut disorders, medicated vitamins and hospital injectables. The company's best sellers are Maxigesic – a paracetamol and ibuprofen combination – and Hylo eye drops. Atkinson says AFT has 'significantly advanced' its push into multiple geographies and expanding its research and development pipeline. 'These efforts have come at the cost of short-term earnings growth, but we are convinced they will deliver growth in long term shareholder value.' During the year AFT launched Maxigesic tablets in the US, having already introduced the intravenous version. AFT also launchd proprietary antiseptic cream in mainland China, the world's second biggest pharma market behind the US. Atkinson cites a pipeline of injectable drugs with a potential market value of over US$400 million. 'I am confident … AFT has reached an inflexion point and can further extend its decades long record for growth and value creation,' Atkinson says. That said, some investors would like earnings to grow at a faster clip. Telix says 2024 was big, 2025 will be bigger Eight years ago, Telix Pharmaceuticals (ASX:TLX) was merely a gleam in the eye of co-founder Dr Chris Behrenbruch, who convinced former Macquarie Banker Kevin McCann to chair the fledgling business. At yesterday's AGM, the board revelled in the progress of Telix, which recorded revenue of $800 million in calendar 2024. This was on the back of the company's flagship prostate cancer imaging agent, Illuccix. 'Last year I stood at this same lectern and said that 2024 would be the biggest year yet for Telix, and that proved to be the case,' Behrenbruch told the gathered faithful. 'I make a similar prediction again for 2025, as we continue to execute on our strategy and continue the momentum we've built.' The US aside, regulators in the UK, several European countries and Brazil have also approved Illucix. 'The Telix brand now stretches as far as the tropical heat of Rio de Janeiro to the wintry climes of Scandinavia,' said McCann, whose literary flourish can be excused given he retired at the meeting. While most of Telix's revenue derives from Illucix, the company has also commercialised Gozellix (also for prostate cancer imaging) and a lesser-known offering called Scintimun (for imaging bone infections). The company awaits an FDA decision on approving its kidney cancer imaging agent on or before August 27. Telix's holy grail is to develop therapeutic – as opposed to imaging – products. 'We have one of the deepest therapeutic radiopharmaceutical pipelines in the industry,' Behrenbruch said. 'We are poised to have three assets in pivotal trials by the end of this year, comprised of our lead prostate, kidney and brain cancer therapy candidates.' Re-doing the homework Not everything has gone Telix's way, with the FDA last month knocking back the company's US marketing approval application for its brain cancer imaging agent, Pixclara. The FDA issued complete response letter, which demands that an applicant do more homework. Behrenruch said the company met with the FDA to glean what is required. 'At this stage, we believe resubmission in 2025 is achievable,' he said. Behrenbruch adds Telix has focused on developing its supply of isotopes, which need to be manufactured close to the patient. 'As most investors understand by now, there is no 'magic isotope store in the sky' and no 'man with a van' that turns up with a product,' he said. 'Radiopharma is a logistically and supply-chain intensive field of medicine. "The network of capabilities that we have built – and bought – is critical for the reliable delivery of just-in-time manufactured products like ours.' Manufacturing in the US – where most of Telix's patients currently reside – has a flow-on benefit of 'managing the risk of tariffs and other trade barriers affecting the supply and cost of our products.' As of the end of March, Telix had cash of $710 million. Given the company has set a minimum cash buffer of US$100m ($156 million), that implies plenty more firepower for acquisitions or shareholder returns. Dimerix trial passes safety audit – again Long-running and expansive trials are all about the little moments along the way – and Dimerix (ASX:DXB) has chalked up another one with its pivotal phase III kidney disease study. In its sixth review of the trial, the US-based Independent Data Monitoring Committee (IDMC) recommends the trial, dubbed Action3, continue unchanged. 'The IDMC has again noted no safety concerns to date, consistent with their prior reviews and the existing and emerging strong safety profile of (the drug candidate) DMX-200,' the company says. The IDMC will take another peek in the December quarter. DMX-200 tackles the rare kidney disease focal segmental glomerulosclerosis, for which there is no effective treatment. Meanwhile, Blinklab (ASX:BB1) has secured its first clinical site for its pivotal trial of its autism detection algorithm, pitched at FDA approval. The company has enrolled 100 patients in the initial stage, with an additional 750 to 900 participants undergoing testing thereafter. The first site is the Arizona based Southwest Autism Research & Resource Center. Blinklab expects to be able to file an FDA submission in the March quarter of next year, using the 510(k) route.
Business Insider
12-05-2025
- Business
- Business Insider
Wilsons Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Wilsons analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals (TLPPF – Research Report) on May 8 and set a price target of A$35.00. The company's shares closed last Friday at $17.88. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Nanosonics Limited, and Opthea . According to TipRanks, Storey has an average return of 9.9% and a 53.46% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Telix Pharmaceuticals with a $21.77 average price target, representing a 21.79% upside. In a report released on April 29, Bell Potter also maintained a Buy rating on the stock with a A$34.00 price target. The company has a one-year high of $24.85 and a one-year low of $9.60. Currently, Telix Pharmaceuticals has an average volume of 7,300.
Business Insider
29-04-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Telix Pharmaceuticals (OtherTLPPF) and Alnylam Pharma (ALNY)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Telix Pharmaceuticals (TLPPF – Research Report) and Alnylam Pharma (ALNY – Research Report) with bullish sentiments. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Telix Pharmaceuticals (TLPPF) Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. The company's shares closed last Monday at $17.00. According to Hester is a 4-star analyst with an average return of 4.8% and a 50.6% success rate. Hester covers the Healthcare sector, focusing on stocks such as Paradigm Biopharmaceuticals, Pro Medicus Limited, and Nanosonics Limited. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Telix Pharmaceuticals with a $21.88 average price target, representing a 28.7% upside. In a report issued on April 22, TD Cowen also maintained a Buy rating on the stock with a A$35.00 price target. Alnylam Pharma (ALNY) TD Cowen analyst Ritu Baral maintained a Buy rating on Alnylam Pharma today and set a price target of $371.00. The company's shares closed last Monday at $254.85. According to Baral is a 3-star analyst with an average return of 2.0% and a 39.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Milestone Pharmaceuticals, and Sionna Therapeutics, Inc. Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $312.95, a 23.8% upside from current levels. In a report issued on April 15, Evercore ISI also maintained a Buy rating on the stock with a $280.00 price target.
AU Financial Review
28-04-2025
- Business
- AU Financial Review
Telix setback in drug approval in US, amid Trump workforce cuts to FDA
Telix Pharmaceuticals says it is disappointed by a surprise US Food and Drug Administration decision to ask for more clinical evidence to support approval for its brain cancer imaging agent, a rare setback for the $9 billion ASX-listed diagnostic giant. Telix shares fell as much as 10 per cent in early trading on Monday after the FDA said it would not approve the company's diagnostic tool called Pixclara, which identifies gliomas, a deadly form of brain cancer, until the company provided additional evidence about its benefits.
